We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Tyratech (DI/S) | TYR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.95 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.95 | 2.95 |
| Top Posts |
|---|
Posted at 15/9/2017 21:20 by thegrumpster This has to be one of the most disappointing shares on AIM. They just do not seem to be able to make a go of anything.Used to be in this one years and years ago (2009? Pre TYRU) Actually made a bit of money when everything on AIM was going up. Got out because of some "dodgy" fund was involved (supposedly known for lending money, then pulling the plug)...they've gone. And there were too few trades....first person to sell crashed the share price. The University also seemed to be sliding out quietly....didn't seem to take part in additional fundraising, and they're not short of a bob or two. Lack of faith in their own technology, or the people running the company? The opportunities for their products are still out there. This for example, still relevant: ""According to Edinburgh University's Centre for Tropical Medicine, midges respond to the combination of chemicals - including lactic acid - present in the sweat of certain people, which they detect via their highly sensitive antennae. Research is focusing on the development of a repellent that can block receptor sites on midge antennae, but until such a product becomes available, those of us who are vulnerable must find other ways to manage the midges." "....It is estimated that midges cost the Scottish tourist industry up to £268 million a year in lost revenue, because many avoid visits during midge season. A forestry study carried out in the mid-1980s also suggested that 20 per cent of working days were lost because clouds of biting midges make timber felling and tree planting nigh impossible."" £268 million ten years ago. What are they losing now with the low pound, and the UK being a cheap destination for holidays? Midges? 2007 Tyratech 480p +20 Questor says Buy (Those were the days ....480 pee) "The arrival in the UK of the bluetongue virus this week, blown into the country by midges, served as a useful reminder than insect bites are not just a pain in the proverbial. They can devastate farmers' livelihoods and have brought animal movements across East Anglia to a complete halt. So it was particularly timely for Tyratech to publish its maiden results yesterday. The start-up (it listed on Aim this summer) is among a new breed of companies creating technology that should help create potent pesticides out of natural materials. It has located a number of receptors in parasites and insects that react to natural products. While this has been done before, the results have not always been totally effective. Tyratech claims to have taken the development a stage further, so that its plant-based products are now more powerful than chemical rivals. The potential benefits are enormous. Tyratech's natural products do less damage to the environment – increasingly important –as well as offering an alternative against insects that have developed a resistance to traditional products. What is more, as the receptors in insects are not found in mammals, the pesticides are literally fit to drink, and Tyratech is hoping to develop products that can combat intestinal parasites. As an investment case, the potential is clear but the risks are great. Tyratech's products are novel and it does not have a proven track record. The shares trade on a multiple of 30 times forecast earnings for 2009 (the first year it is expected to make a profit) falling to five times for 2011. It is not one for short-term investors or the risk-averse, but for others it's worth a punt." Seem to remember it was only about 30,000 shares sold, that brought it finally down to about 12p, in 2008, when things started looking ropey. They've even got a product. Hopeless innit. |
Posted at 08/4/2015 08:59 by gemferret Nobby/Michaelre 'it is amazing there is no interest here.' There interest form lurkers like me who don't take what the company say at face value. EG I spotted there was something up re the Terminix deal (Walmart and Home depot). Now it's clear to all that product is not on sale at either store. In other words it's fallen through. Tyr are keen to update the market on deals to put products on shelves, but stone wall any questions about that the terminix Walmart situation. The company, nomad or anyone else won't answer the questions, so a lack of trust in what they, release naturally embeds itself. Then you add on what is rumoured. EG rumoured claims by Eden (probably sour grapes)nthat TYR overstate things and it's not always as it seems. That was pre the Terminix 'issues'. Add on the pumping by the untrusted professional tipsters well known for their games historically. We know the UK launch cost a decent amount and it seems they struggled to get the products on shelves. So how are they going to get the product on all the shelves they have mentioned recently. It's going to cost quite a bit up front. Add in the team salaries and it's a small company with a high cash burn, regardless of R and D. plus launch costs. Note they said they have enough cash for launches. To the average investor that means they don't need cash/dilution. To the glass half empty views, it means they have enough cash for launches, but not the day-to-day running of the business. So on my side of the fence dilution has been on the way for some time. Therefore I'm waiting to see how much cash they need and what dilution effect that will have. Vamousse was late launching (UK), The Novartis product launches have been delayed, the Terminix Walmart/Homedepot side of Envance is dead. They said they would advertise Vamousse and they have done very little. That suggests the budget won't allow it. It was the wrong approach in the advert anyway in my opinion, non chemical and safe is a very key advantage but they don't mention it in the advert. ??? Another red flag (to me) is that they have been keen to announce further deals for Vamousse, but at no time recently have they taken the opportunity to mention how sales are going. So I'm waiting to see a detailed update and I expect that to include fund raising in the near future. I want to see what dilution that creates, and what they are going to spend it on. That combined with details of how product launches are going. So yes there is interest lurking. Some very good looking products and potential, but at this price how many £millions do they need. It could be quite a sizeable dilution coming up. |
Posted at 24/11/2014 16:20 by gemferret BrianThe repellent is seasonal and dropped into the game at the wrong end of those, so that won't kick in until H2 next year. There were also some apparent delays in getting Vamousse launched on time in the UK. The advert period on the TV seemed to be post schools returning in September. I saw a number of competitor commercials but not Vamousse. The two big claims are 100% kill rates and chemical free. Others twist their words to make it sound like it's 100% effective, so the non chemical angle was a big point which they seem to have ignored in the advert ??? There was a debate about nits recently in a typical high viewer slot. Just combing to avoid the using the chemical loaded products came up, but no mention of products that are chemical free like Vamousse. I believe they will be way off 2nd half forecast revenue, and will need funds due to their cash burn rate. I really like the idea and products but hey cam take time to gain traction in the market. I don't like the way the company refuses to comment on matters that some consider material. For now it seems they couldn't give a toss about private investors. So if the mysterious drift on the share price is supported by a fund raise and revenues not as forecast, then the insti's have been aware for a while. |
Posted at 23/11/2014 17:13 by gemferret I'm still tracking it too. I see no products of the Terminix brand seem to be listed with Walmart or Home depot any more so my findings were spot on.I wish Tyratech would stop hiding behind the no obligation (40% of envance) smoke screen, and tell investors wtf is going on with that terminix deal. AIM is a pit with very few that can be trusted so they need to answer questions if they want investor confidence in their company. Once they sort out the next round of funding hopefully that will be it the last time they need to. |
Posted at 14/9/2014 09:35 by gemferret Still lurking and getting a getting grip of this now.It looks like it is a company with great prospects, but then why aren't the major buyers out there. What it currently has is PI spike buying on any news, and that's it. The funds and larger investors are not buying as it seems there will be another bout of fund raising near term, they got them at 7p last time. The spikes suggest shares are tight so they can't get them on the market (if they want them) Why more funding? Tyr reported this for the last funding, with about 700k in the bank at the time ◦£1.5 million to support the launch of the Vamousse product range in Boots and Superdrug in the UK through a focused marketing campaign and to build up the appropriate inventory; ◦£1.2 million for further anticipated listings in additional US and UK retailers as well as expansion into further new geographic regions; and ◦£0.6 million for additional working capital. So 600k left for additional working capital on top of the 700k. Last results $2.8 mill General which will include salaries $430k business development $1.75 mill R and D. That's a $400k per month burn rate. I note the talk of 10's of 1000's of the Vamousse product sold. Call it 80,000 and £5 profit per unit and you have £400k ($650). So 6 weeks worth of the cash burn rate. However I think they have a supply problem as Superdrug while listing it seems to show they have no stock. Boots doesn't appear to list it currently. Going back to the fund raising comment. 'and to build up the appropriate inventory;' So it seems they don't have the supply capacity at the moment but will do in the future. The head lice season is short in terms of product demand. 10's of 1000's and 100's of 1000's are nowhere near enough to cover costs. That's ignoring the months of payment lag from the partners they are with. Then of course there are plenty of other products out there. I know Vamousse seems far better, but I have had success with the other products, and know it they cover multiple treatments, not just one per child. So there is quite a lot of cash needed yet whether through debt or dilution, in the coming months. There is no way sales are going to cover costs. Guardian, although launched won't see winter sales, that will be a spring/summer product Anyone any idea of the likely amount they will need. My guess is $5 to $10 mill overall before Tyr can get to positive cash flow. They have done about $5.4 mill this year so far, the first one earlier in the year included the comment to build an appropriate Vamousse inventory, which would have been the US side. They also said this on the last one 'as well as expansion into further new geographic regions' So they will need funds for the inventory for those areas and other points to. I completely ignore the Envance now, as I see virtually no revenue coming from that direction. I really like the Novartis deal, but it will take time to gain traction in the market, but should do very well. As for now, it's going to be PI spike buying and selling and hype, funds simply won't get involved as it seems for sure another round or two of fund raising is coming. |
Posted at 31/8/2014 22:23 by gekko68 Any question you could phone this number or even send them a letter.For investor relations, please contact: SPARK Advisory Partners Ltd 5 St John’s Lane London EC1M 4BH +44 (0)20 3368 3551 |
Posted at 31/8/2014 21:10 by casablanca4 Agree. Radio is powerful relatively cheap disseminator. Was going to contact TYR but no email contact for investors. Anyone got one. |
Posted at 16/8/2014 19:48 by gemferret Still some hurdles to be negotiated for me, as below.I see the regulated shares keep dropping and that will be those on the US side closer to the company This may be a contributory factor to the apparent sudden cessation of the sale of Terminx through the JV Envance. As you will see below since about April 14 Elevance (looks like it's something to do with the chem giant BASF) has taken action to stop the name Envance becoming a trademark, as below. Initial request 'This company Elevance Renewable Sciences has filed for the opposition of the trademark name Envance technologies.' Latest request sent on 24th July The request to extend time to oppose is granted until 9/14/2014 on behalf of potential opposer BASF Corporation Please do not hesitate to contact the Trademark Trial and Appeal Board at (571)272-8500 if you have any questions relating to this extension. The nomad won't speak, the company won't respond, the Terminix brand product is dropping off shelves, BASF are challenging the trademark, the US regulated share price continues to fall. I suspect Terminix have pulled the plug due to the legal challenge, as they I'm sure they wouldn't want their name dragged into the trademark issue. "Um, er, dormant" now speaks volumes. Hence, I want to know, and believe investors have a right to know, what is going on with Terminix, the JV, and now the Envance name. Overall it is not an issue but currently the company news and circumstances suggest the Terminix product is within a JV, and actively being sold in the US, which is clearly not the case. |
Posted at 11/8/2014 17:07 by gemferret No nothing else to worry about just the 24% and no I think there is no chance AMVAC will hold a position if terminix and the Envance deal is off.Yes I think others funds or investors could hoover them up and probably will, but if right I would like to see the findings in the public domain. I would personally like that uncertainty out of the way. I'll hang fire for a company response. If no response I'll nag the nomad for information. Great looking company and a great team, just some short term loose ends for me, and I'm doing my best to tie them up. I will share any info if I get any. I like the situation of products launched and launching. I'm sick to death of others I'm interested in, and their promises of launch. It never seems to happen. Tyra have done, and are doing what others should do, grasp the nettle and get on with it. |
Posted at 09/8/2014 20:23 by gemferret Perhaps I am misunderstood,I think vamousse is fab and will sell like mad, it completely slaughters US similar products. Here is my very heavy concern short term, It's not about investors that understand Tyratech, but those invested that don't. A deal was done for the Terminix brand name. Then Tyra linked with AMVAC, then came the 60/40 Envance. Envance deal with terminix. Amvac took 29.46% of Tyratech. The current shareholding is shown as .....American Vanguard Corp 24.09%. Currently there in no public news saying the Terminix deal is dead. So personally I would like to know officially that the Terminix deal has gone and then I want to know what investors reactions are going to be when they realise the AMVAC connection also has a track into Terminix via envance. Will Amvac offload, or more importantly will investors sell thinking Amvac will offload as Tyra seem to have moved over to Novartis. It's just a move, but Amvac have a large shareholding and I have no idea if they would exit if the terminix deal is off. Fear is often more damaging than fact, so if terminix is off the table, then spell it out and what it means about the close association with Amvac. Those terminix products now seem to be with Novartis. I would like confirmation from the company what is going on, so I can consider if AMVAC will remain as a major shareholder, and how the market will react to such potential news. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
